Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting

Organogenesis Holdings Inc.

Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.
All nine director nominees elected; Garrett Lustig re-elected via Series A written consent with vote tallies of ~72M for.
Advisory 'say-on-pay' proposal approved with 67.1M votes for, 6.3M against.
Ratification of RSM US LLP as independent auditor for FY2025 passed with 103.6M votes for, 3.9M against.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.